Active, not recruitingNot applicableNCT01049230
Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors
Studying Tumor of testis and paratestis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Shannon MacDonald, MDMassachusetts General Hospital
- Intervention
- Proton Beam radiation(radiation)
- Enrollment
- 45 target
- Eligibility
- 3-25 years · All sexes
- Timeline
- 2010 – 2027
Study locations (2)
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
Dana-Farber Cancer Institute · National Institutes of Health (NIH)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01049230 on ClinicalTrials.govOther trials for Tumor of testis and paratestis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06593665Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.Indiana University
- RECRUITINGPHASE2NCT06144736PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLNDHeinrich-Heine University, Duesseldorf
- RECRUITINGNCT05564026Molecular Epidemiology of Pediatric Germ Cell TumorsChildren's Oncology Group
- RECRUITINGPHASE2NCT05529251De-escalation Study for Stage IIa/IIb < 3 cm SeminomaCentre Leon Berard
- ACTIVE NOT RECRUITINGPHASE2NCT03937843Reduced Intensity Radio-chemotherapy for Stage IIA/B SeminomaSwiss Cancer Institute
- RECRUITINGNANCT04113122Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT StudyUniversity Medical Center Groningen
- ACTIVE NOT RECRUITINGPHASE2NCT03158064Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsMemorial Sloan Kettering Cancer Center